Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.74 SEK | +4.72% | +8.86% | +13.51% |
18/04 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
18/04 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 166
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody-cleaving Enzyme Technology Platform
100.0
%
| 155 | 100.0 % | 134 | 100.0 % | -13.22% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe (excluding Sweden)
79.6
%
| 86 | 55.4 % | 107 | 79.6 % | +24.66% |
North America
20.4
%
| 64 | 41.6 % | 27 | 20.4 % | -57.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20/18/20 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29/20/29 |
- | - | ||
Klaus Sindahl
IRC | Investor Relations Contact | - | 29/19/29 |
Matthew Shaulis
PRN | Corporate Officer/Principal | - | 16/23/16 |
Max Sakajja
PRN | Corporate Officer/Principal | 43 | 01/17/01 |
Anne Lanner
HRO | Human Resources Officer | 55 | 18/19/18 |
Vincenza Nigro
PRN | Corporate Officer/Principal | - | 17/18/17 |
Magnus Korsgren
PRN | Corporate Officer/Principal | 55 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 29/18/29 | |
Peter Nicklin
CHM | Chairman | 61 | 30/22/30 |
Mats Blom
BRD | Director/Board Member | 59 | 22/19/22 |
Eva Nilsagård
BRD | Director/Board Member | 60 | 22/19/22 |
Hilary Malone
BRD | Director/Board Member | 59 | 12/21/12 |
Andreas Eggert
BRD | Director/Board Member | 56 | 29/18/29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,362,445 | 0 | 2,362,445 ( 100.00 %) | 88.64 % |
Stock B | 1 | 52,443,962 | 48,580,000 ( 92.63 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
HANSA BIOPHARMA AB 100.00% | 2,598,012 | 100.00% | 7,070,516 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.51% | 152M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- HNSA Stock
- Company Hansa Biopharma AB